ClearPoint Neuro's (CLPT) Strategic Milestones and Market Performance
ClearPoint Neuro's (CLPT) Strategic Milestones and Market Performance
ClearPoint Neuro, Inc. (NASDAQ: CLPT) shares maintained stability during the preceding session, concluding at $6.05, with a modest uptick of 0.33%. This steadiness in CLPT stock price followed the release of its quarterly financial outcomes. ClearPoint Neuro (CLPT) unveiled its financial performance for the fourth quarter and full fiscal year ending on December 31, 2023.
ClearPoint Neuro, Inc.（納斯達克股票代碼：CLPT）股價在前一交易日保持穩定，收於6.05美元，溫和上漲0.33％。CLPT股價的這種穩定是在其季度財務業績公佈之後出現的。ClearPoint Neuro（CLPT）公佈了截至2023年12月31日的第四季度和整個財年的財務業績。
The company affirmed its performance for the fourth quarter of 2023, which encompassed remarkable revenue figures of $6.8 million, indicating a growth of over 30% in its topline, and a reduction in quarterly cash expenditure to a mere $1.2 million, marking its lowest point since 2020. Notably, within the initial two months of 2024, CLPT has already attained several significant strategic milestones.
該公司確認了其2023年第四季度的業績，其中包括680萬澳元的驚人收入數字，表明其收入增長了30％以上，季度現金支出減少至僅120萬美元，創下2020年以來的最低點。值得注意的是，在2024年的前兩個月內，CLPT已經實現了幾個重要的戰略里程碑。
These milestones include multiple FDA clearances and inaugural human procedures, initial shipments to European Union nations from its recently established Carlsbad facility, endorsed under EU-MDR certification, publication of pivotal validation studies in peer-reviewed journals endorsing both its navigation software and laser therapy system, and the acquisition of more new clinical clientele in the first quarter alone than throughout the entirety of 2023.
這些里程碑包括多次獲得美國食品藥品管理局的批准和首次人體手術，從其最近成立的卡爾斯巴德工廠首次向歐盟國家發貨，並獲得歐盟MDR認證的認可，在同行評審期刊上發表認可其導航軟件和激光治療系統的關鍵驗證研究，以及僅在第一季度就收購了比2023年全年更多的新臨床客戶。
Furthermore, ClearPoint Neuro also announced this week the publication of preclinical findings from an in vivo validation study in the Journal of Neurosurgery. These findings underscore the capability of the ClearPoint Prism Neuro Laser Therapy System in providing precise, nearly real-time brain tissue temperature measurements with a mean absolute error of less than 1°C.
此外，ClearPoint Neuro本週還宣佈在《神經外科雜誌》上發表一項體內驗證研究的臨床前發現。這些發現突顯了ClearPoint Prism神經激光治療系統能夠提供精確、近乎實時的腦組織溫度測量，平均絕對誤差小於1°C。
Additionally, the observed lesion morphology, as depicted by Thermoguide MR-thermometry software, exhibited a strong correlation with histopathological assessments. Conducted collaboratively by the Company and its Swedish partner, Clinical Laserthermia Systems AB (CLS), under the leadership of Dr. John Rolston as the Principal Investigator, the study aimed to assess the safety, accuracy, and efficacy of the Prism System.
此外，正如Thermoguide MR-Thermotrey軟件所描繪的那樣，觀察到的病變形態與組織病理學評估顯示出很強的相關性。該研究由該公司及其瑞典合作伙伴Clinical Laserthermia Systems AB（CLS）合作進行，由首席研究員約翰·羅爾斯頓博士領導，旨在評估棱鏡系統的安全性、準確性和有效性。
This was achieved by demonstrating a predictable safety margin through survival histology, identifying Thermal Damage Thresholds (TDTs) that best forecast irreversible tissue damage based on histological evidence, and assessing the accuracy of temperature predictions against actual in vivo temperature changes.
這是通過生存組織學證明可預測的安全邊界來實現的，根據組織學證據確定最能預測不可逆組織損傷的熱損傷閾值（TDT），以及根據實際體內溫度變化評估溫度預測的準確性。
譯文內容由第三人軟體翻譯。